Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
Status:
Recruiting
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate whether the combination of Pembrolizumab
and Axitinib given in the neoadjuvant setting can change the Inferior Vena Cava Tumor
Thrombus burden. A decrease in the size of the tumor thrombus can potentially lead to
decrease in surgical complications, improve patient related health outcomes, and improve long
term outcomes such as progression free survival and overall survival.